Abbott stent outperforms rival from Boston Sci

Abbott Laboratories' Xience V stent prevented more heart attacks with fewer complications after two years than Boston Scientific's rival Taxus Express, a study has found. Patients with the Abbott stent were 30 percent less likely to have a heart attack or other major stent failure than those given Boston Scientific's Taxus Express, Abbott-sponsored researchers found. Blood-clot formation, a serious complication, occurred 64 percent less often in the Xience group, Bloomberg reports. Article

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.